The BNP gene polymorphism as a regulator of brain natriuretic peptide plasma level in men with uncomplicated essential hypertension and left ventricular hypertrophy

Aim: The BNP biomarker application optimization for myocardial dysfunction diagnosis in men citizens of Podillia region in Ukraine with uncomplicated essential hypertension and left ventricular hypertrophy by determining the plasma levels in patients with different BNP gene variants. Methods. We examined 141 men, age 40 – 60 years, who live in Podillia region. Among them 62 men were diagnosed uncomplicated EH with left ventricular hypertrophy (stages 1 and 2) and CHF I-II classes according to NYHA Classification. 79 healthy men were included into the control group. The patients with uncomplicated EH and the healthy men were representative by age. The BNP (T-381C) gene polymorphism was determined by PCR, and the level of BNP plasma concentrations was established by ELISA. Results. In both healthy men and patients with uncomplicated EH with LVH, residents of Podillia region, age 40-60 years, dominates the T381C genotype and the C allele of the BNP gene. It was found that any inherited variant of the BNP gene was not associated with the risk of developing uncomplicated EH with LVH in men residents of Podillia region. However, carriers of the C381C genotype and the C allele of the BNP gene have significantly higher levels of BNP in plasma in both healthy men and patients with uncomplicated EH and LVH, residents of Podillia region, age 40-60 years. There are calculated levels of BNP that can be used for screening of large groups of people for early diagnosis of uncomplicated EH with LVH: BNP boundary level ≥ 82,41 pg/ml ables to diagnose uncomplicated EH with LVH in male carriers of the C allele heterozygote carriers of the genotypes T381C and C381C of the BNP gene; BNP boundary level ≥ 45,34 pg/ml ables to diagnose uncomplicated EH with LVH in male homozygote carriers of the T381T genotype of the BNP gene.